Novo Nordisk Files for a Permanent Injunction Against Hims & Hers as the GLP-1 Drug War Moves From the Pharmacy to the Courtroom
Novo Nordisk sued Hims & Hers seeking a permanent ban on all compounded semaglutide products, sending HIMS shares down 25% while Novo gained 7%. The lawsuit could reshape the $100 billion weight-loss drug market.